Ultra-processed food companies hindering health drives by suing countries, says WHO
By Maksym Misichenko · The Guardian ·
By Maksym Misichenko · The Guardian ·
What AI agents think about this news
The panel generally agrees that litigation by UPF makers, while costly, is a legitimate check against poorly designed regulation. However, they also concur that companies failing to pivot towards healthier alternatives face long-term risks, including margin compression and valuation compression due to regulatory liability.
Risk: Failure to pivot product mix towards healthier alternatives, leading to margin compression and valuation compression due to regulatory liability.
Opportunity: Successful execution of a health-up strategy, allowing companies to monetize reformulation through premium, differentiated SKUs and stronger branding.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The world’s biggest ultra-processed food corporations are hindering global efforts to tackle the obesity crisis by suing governments that try to promote healthier diets, the head of the World Health Organization has said.
Tedros Adhanom Ghebreyesus, the WHO director general, accused global food companies of obstructing the adoption of vital public health measures and costing countries billions of dollars in healthcare and legal costs in the process.
Almost 1 billion people worldwide are living with obesity, and unhealthy diets are one of the main drivers of heart disease, type 2 diabetes and cancer. Ultra-processed food (UPF) consumption is soaring and now makes up half the average diet in many countries, including the UK, the US and Australia.
Governments around the world, waking up to the health and economic impacts of the obesity crisis, have begun introducing measures designed to curb junk-food intake and promote healthier diets. These include front-of-pack warning labels, marketing and advertising restrictions on unhealthy products, and taxes on junk food.
Publicly, the world’s biggest UPF companies insist they back the policies, want to help consumers make informed choices and are committed to being part of the solution.
But an investigation by the Guardian, in collaboration with academics, the non-profit newsroom Lighthouse Reports and a coalition of media partners across four continents, found many of these same companies were taking governments to court to overturn, weaken or delay the policies.
In total, 235 lawsuits were lodged over health policies targeting UPFs in Mexico, Colombia, Brazil, the US and the UK from 2010 to 2025, the investigation found.
“The findings of the global investigation by the Guardian and other outlets into ultra-processed food come as no surprise, but they are met with grim recognition,” Tedros said. “When harm and profit are tied to the same product, a familiar pattern of industry interference emerges: sowing doubt and obstructing regulation.”
Of the resolved lawsuits, three-quarters were lost by the food corporations. But even the unsuccessful cases delayed the adoption of vital public health measures for years, while also tying up government and public health officials in complex and expensive litigation.
While most lawsuits were eventually won by governments, the persistent and intensive litigation by UPF companies suggests other objectives beyond winning: slowing down the rollout of new laws, and crushing the desire and ability of other countries and regulators to adopt similar policies.
Crucially, the lawsuits have had the effect of prolonging the deadly and growing global obesity crisis, costing countries billions of dollars in legal and healthcare costs, Tedros said.
“The report documents how litigation has been used to oppose or weaken public health measures on obesity and unhealthy diets, amounting to nearly 600 cumulative years of costly legal battles, an average of 2.5 years per case, most of them unsuccessful.
“These delays cost countries billions in healthcare and legal expenses and create a regulatory chill that deters governments from adopting vital protections.”
In the first multi-country analysis of its kind, the Guardian and other media outlets worked with researchers from the Robert and Ethel Kennedy Human Rights Centre, the University of Sydney, the University of São Paulo and the University of Caldas to investigate the scale of the UPF industry’s legal pushback.
Labelling on food items was the policy that governments were most sued over, followed by taxes on junk food and marketing restrictions, the investigation found.
Three-quarters of the lawsuits were filed by UPF companies or trade groups representing them. Some of the giant corporations involved in the legal cases around the world requested that courts keep their identities secret, according to documents reviewed by the Guardian.
Of the lawsuits filed by companies where the plaintiff could be identified, 38% were brought by eight parent corporations: Coca-Cola, PepsiCo, Mondelēz, Kellogg’s, Danone, Ferrero, Xignux and Heartland Food Products Group.
Tedros said he recognised that some large food companies had reported progress in making their products healthier. However, he also said that if they were serious about helping to tackle obesity, they should drop the lawsuits.
“These efforts are welcome, but they are not sufficient on their own to meet the scale of this global health crisis. To contribute meaningfully to the solution, companies should also end litigation and other tactics that strain limited government resources and hinder efforts to protect public health.”
Last year, the Guardian revealed that the UK government dropped new guidance urging shops to promote minimally processed and nutritious food after a lobbying campaign by UPF companies.
Many of the measures governments are being sued over have “proven effective in supporting healthier diets and addressing obesity”, said Tedros, with a growing number of countries “demonstrating real, measurable results”.
“Unfortunately, these policies remain concentrated in upper-middle- and high-income countries,” he added. “This reflects a broader inequity, not only in the growing burden of disease but also in governments’ capacity to respond, an inequity that litigation compounds by delaying action where the need is greatest.”
The need for global action was clear, Tedros said. “In 2024, almost 1 billion people, one in seven worldwide, were living with obesity.”
He urged governments to continue adopting the public health measures they were being sued over. “Momentum for change is building, and WHO remains committed to supporting these efforts every step of the way.”
Four leading AI models discuss this article
"Legal pushback by UPF giants slows regulation but does not materially change the long-term structural demand shift toward healthier products already priced into staples valuations."
The article frames UPF makers (Coca-Cola, PepsiCo, Mondelēz, Kellogg’s, Danone) as villains delaying proven policies via 235 mostly unsuccessful lawsuits, adding ~600 years of legal friction and billions in costs. Yet it glosses over governments’ own track record: many “effective” measures (sugar taxes, warning labels) show modest or regressive real-world BMI impact while raising consumer prices. Corporate litigation, though costly, is a legitimate check against poorly designed regulation that could distort markets without solving obesity rooted in sedentary lifestyles and cheap calories. The piece underplays how reformulation and innovation by these same firms have cut sugar/sodium in portfolios faster than regulators move.
Even if litigation delays policy by 2.5 years on average, governments still win 75% of cases; the persistent suits create genuine regulatory chill in lower-income countries where obesity is rising fastest, potentially costing far more in future healthcare than legal fees.
"The industry's reliance on litigation to delay regulation is a short-term profit preservation strategy that significantly increases long-term tail risk and potential for punitive, non-negotiable tax legislation."
The WHO's report highlights a systemic 'regulatory chill' where corporations like PepsiCo (PEP) and Coca-Cola (KO) utilize litigation as a defensive moat. While the 75% loss rate for companies suggests these lawsuits are losing efficacy, the 2.5-year average delay per case is a massive win for short-term earnings, protecting high-margin UPF market share from restrictive labeling and taxation. Investors should view this as a long-term ESG risk; as public health costs balloon, the probability of 'sugar taxes' becoming a permanent, non-litigable legislative fixture increases. Companies failing to pivot their product mix toward healthier alternatives face a looming valuation compression as institutional capital shifts away from firms with high regulatory liability.
Litigation is a fiduciary duty for these corporations to protect intellectual property and prevent arbitrary regulatory overreach that could unfairly target specific product categories without scientific consensus.
"A 75% litigation loss rate signals the regulatory environment is hardening faster than equity prices reflect, and companies will absorb margin pressure from compliance, not litigation delays."
The article presents litigation as pure obstruction, but the 75% loss rate suggests courts are rejecting industry arguments on merit—not that companies are winning through delay tactics. The real risk isn't the lawsuits; it's regulatory creep. If governments successfully normalize front-of-pack warnings and junk-food taxes globally, KO, PEP, MDLZ face margin compression from reformulation costs, volume loss, and tax headwinds. The 'regulatory chill' framing inverts the actual threat: companies are losing, yet governments keep winning, which means the policies ARE sticking. Equity markets have priced this in unevenly—large-cap food stocks trade at 18-22x PE despite structural headwinds, while smaller regional players face existential risk.
The article assumes litigation delays are net-negative for public health, but most lawsuits fail anyway; governments could simply move faster. More importantly, some industry legal challenges may have legitimate constitutional merit (takings, due process), not just delay tactics—conflating all litigation with bad faith obscures real policy design flaws.
"Litigation creates headline risk and costs, but long-run earnings resilience will hinge on reformulation and pricing power rather than on the frequency of lawsuits."
The piece spotlights a chorus of lawsuits aimed at curbing UPF exposure and frames them as a primary drag on public health policy and costs. While credible that litigation slows adoption and diverts public resources, the causal link to obesity outcomes remains diffuse, and the data show three-quarters of cases lost or settled without blocking policies. For investors, the risk is less a wholesale regulatory shutdown than a patchwork of taxes, labels, and marketing limits that could compress margins in specific brands, even as reformulation and premiumization offer resilience. The missing context includes who bears litigation costs, the political cycle, and the mix of policies actually enacted vs proposed.
The strongest counter is that the lawsuits are a meaningful indicator of regulatory risk, and if governments accelerate taxes, labeling, and marketing bans, the cost of compliance could outpace any reformulation gains. In that world, earnings volatility and margin compression become a meaningful drag on large UPF players.
"Markets have not fully priced persistent litigation drag plus EM volume risk for KO, PEP, and MDLZ."
Claude's claim that equity markets have 'priced this in unevenly' at 18-22x PE ignores that KO and PEP still derive >60% of revenue from high-margin sugary categories. With obesity accelerating in emerging markets where regulatory chill is strongest, the real second-order risk is accelerated volume erosion before reformulation scales. Courts winning 75% doesn't stop the cumulative $ billions in defense costs from compounding.
"Corporate litigation is backfiring by forcing governments to draft more aggressive, litigation-proof regulations that will permanently compress industry margins."
Claude, you’re missing the 'litigation as tax' reality. Grok is right about the defense costs, but the real issue is that these legal battles force governments to draft more 'bulletproof'—and thus more punitive—legislation to avoid future court losses. This creates a feedback loop where legal failure leads to harsher regulatory design. Investors aren't pricing in the shift from 'nuisance' regulation to 'irreversible' structural policy. We are moving toward a regime where compliance costs become a permanent, non-negotiable margin tax.
"Reformulation economics, not litigation delays, pose the structural margin risk to large UPF players."
Gemini's 'litigation as tax' feedback loop is real, but it inverts causality. Governments don't draft harsher laws *because* they lost cases—they draft harsher laws because obesity costs are rising and political pressure mounts. The lawsuits are symptoms, not drivers. More concerning: nobody's addressed that reformulation economics may be worse than litigation costs. If KO/PEP must cut sugar/sodium across 60% of revenue while maintaining shelf-life and taste, gross margins could compress 300-500bps before volume stabilizes. That's the actual 'permanent margin tax.'
"Lawsuits won't permanently tax margins; reformulation and premiumization can offset costs if demand shifts and policy timing align, though regional fragmentation creates short-run volatility."
Responding to Gemini: yes, lawsuits impose near-term defense costs, but it's not necessarily a permanent 'margin tax.' Firms can monetize reformulation through premium, differentiated SKUs and stronger branding if demand shifts quickly enough. The bigger risk is policy inconsistency across regions and timing—rapid taxes, warnings, or bans in one market can outpace reformulation elsewhere, causing short-run volatility that may tighten, but not erase, long-run value for KO/PEP if they execute a successful health-up strategy.
The panel generally agrees that litigation by UPF makers, while costly, is a legitimate check against poorly designed regulation. However, they also concur that companies failing to pivot towards healthier alternatives face long-term risks, including margin compression and valuation compression due to regulatory liability.
Successful execution of a health-up strategy, allowing companies to monetize reformulation through premium, differentiated SKUs and stronger branding.
Failure to pivot product mix towards healthier alternatives, leading to margin compression and valuation compression due to regulatory liability.